Literature DB >> 20558371

Recent advances in neuroblastoma.

John M Maris1.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20558371      PMCID： PMC3306838          DOI： 10.1056/NEJMra0804577

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  66 in total

1.  Copy number variation at 1q21.1 associated with neuroblastoma.

Authors:  Sharon J Diskin; Cuiping Hou; Joseph T Glessner; Edward F Attiyeh; Marci Laudenslager; Kristopher Bosse; Kristina Cole; Yaël P Mossé; Andrew Wood; Jill E Lynch; Katlyn Pecor; Maura Diamond; Cynthia Winter; Kai Wang; Cecilia Kim; Elizabeth A Geiger; Patrick W McGrady; Alexandra I F Blakemore; Wendy B London; Tamim H Shaikh; Jonathan Bradfield; Struan F A Grant; Hongzhe Li; Marcella Devoto; Eric R Rappaport; Hakon Hakonarson; John M Maris
Journal:  Nature       Date:  2009-06-18       Impact factor: 49.962

2.  Overall genomic pattern is a predictor of outcome in neuroblastoma.

Authors:  Isabelle Janoueix-Lerosey; Gudrun Schleiermacher; Evi Michels; Véronique Mosseri; Agnès Ribeiro; Delphine Lequin; Joëlle Vermeulen; Jérôme Couturier; Michel Peuchmaur; Alexander Valent; Dominique Plantaz; Hervé Rubie; Dominique Valteau-Couanet; Caroline Thomas; Valérie Combaret; Raphaël Rousseau; Angelika Eggert; Jean Michon; Frank Speleman; Olivier Delattre
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

3.  The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.

Authors:  Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

4.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

Review 5.  Inhibition of ALK signaling for cancer therapy.

Authors:  Yael P Mossé; Andrew Wood; John M Maris
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

6.  Oncogenic mutations of ALK kinase in neuroblastoma.

Authors:  Yuyan Chen; Junko Takita; Young Lim Choi; Motohiro Kato; Miki Ohira; Masashi Sanada; Lili Wang; Manabu Soda; Akira Kikuchi; Takashi Igarashi; Akira Nakagawara; Yasuhide Hayashi; Hiroyuki Mano; Seishi Ogawa
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

7.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.

Authors:  Isabelle Janoueix-Lerosey; Delphine Lequin; Laurence Brugières; Agnès Ribeiro; Loïc de Pontual; Valérie Combaret; Virginie Raynal; Alain Puisieux; Gudrun Schleiermacher; Gaëlle Pierron; Dominique Valteau-Couanet; Thierry Frebourg; Jean Michon; Stanislas Lyonnet; Jeanne Amiel; Olivier Delattre
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

8.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Authors:  K Beiske; S A Burchill; I Y Cheung; E Hiyama; R C Seeger; S L Cohn; A D J Pearson; K K Matthay
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

9.  Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.

Authors:  Mario Capasso; Marcella Devoto; Cuiping Hou; Shahab Asgharzadeh; Joseph T Glessner; Edward F Attiyeh; Yael P Mosse; Cecilia Kim; Sharon J Diskin; Kristina A Cole; Kristopher Bosse; Maura Diamond; Marci Laudenslager; Cynthia Winter; Jonathan P Bradfield; Richard H Scott; Jayanti Jagannathan; Maria Garris; Carmel McConville; Wendy B London; Robert C Seeger; Struan F A Grant; Hongzhe Li; Nazneen Rahman; Eric Rappaport; Hakon Hakonarson; John M Maris
Journal:  Nat Genet       Date:  2009-05-03       Impact factor: 38.330

10.  Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Authors:  Rani E George; Takaomi Sanda; Megan Hanna; Stefan Fröhling; William Luther; Jianming Zhang; Yebin Ahn; Wenjun Zhou; Wendy B London; Patrick McGrady; Liquan Xue; Sergey Zozulya; Vlad E Gregor; Thomas R Webb; Nathanael S Gray; D Gary Gilliland; Lisa Diller; Heidi Greulich; Stephan W Morris; Matthew Meyerson; A Thomas Look
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962
View more
  740 in total

1.  Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Authors:  E L Carpenter; E A Haglund; E M Mace; D Deng; D Martinez; A C Wood; A K Chow; D A Weiser; L T Belcastro; C Winter; S C Bresler; M Vigny; P Mazot; S Asgharzadeh; R C Seeger; H Zhao; R Guo; J G Christensen; J S Orange; B R Pawel; M A Lemmon; Y P Mossé
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

2.  A small kiss of death for cancer.

Authors:  Angelika Eggert; Johannes H Schulte
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

3.  LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.

Authors:  Shizhen Zhu; Xiaoling Zhang; Nina Weichert-Leahey; Zhiwei Dong; Cheng Zhang; Gonzalo Lopez; Ting Tao; Shuning He; Andrew C Wood; Derek Oldridge; Choong Yong Ung; Janine H van Ree; Amish Khan; Brittany M Salazar; Edroaldo Lummertz da Rocha; Mark W Zimmerman; Feng Guo; Hong Cao; Xiaonan Hou; S John Weroha; Antonio R Perez-Atayde; Donna S Neuberg; Alexander Meves; Mark A McNiven; Jan M van Deursen; Hu Li; John M Maris; A Thomas Look
Journal:  Cancer Cell       Date:  2017-08-31       Impact factor: 31.743

4.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

5.  MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.

Authors:  Brian J Altman; Annie L Hsieh; Arjun Sengupta; Saikumari Y Krishnanaiah; Zachary E Stine; Zandra E Walton; Arvin M Gouw; Anand Venkataraman; Bo Li; Pankuri Goraksha-Hicks; Sharon J Diskin; David I Bellovin; M Celeste Simon; Jeffrey C Rathmell; Mitchell A Lazar; John M Maris; Dean W Felsher; John B Hogenesch; Aalim M Weljie; Chi V Dang
Journal:  Cell Metab       Date:  2015-09-17       Impact factor: 27.287

6.  Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.

Authors:  Brian H Kushner; Irene Y Cheung; Shakeel Modak; Kim Kramer; Govind Ragupathi; Nai-Kong V Cheung
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

7.  Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.

Authors:  Yvette M Carter; Selvi Kunnimalaiyaan; Herbert Chen; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

8.  Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.

Authors:  Erik H Knelson; Angela L Gaviglio; Alok K Tewari; Michael B Armstrong; Karthikeyan Mythreye; Gerard C Blobe
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

9.  TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.

Authors:  Hung C Tran; Zesheng Wan; Michael A Sheard; Jianping Sun; Jeremy R Jackson; Jemily Malvar; Yibing Xu; Larry Wang; Richard Sposto; Eugene S Kim; Shahab Asgharzadeh; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2016-10-10       Impact factor: 12.531

10.  Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Authors:  Julieann Rader; Mike R Russell; Lori S Hart; Michael S Nakazawa; Lili T Belcastro; Daniel Martinez; Yimei Li; Erica L Carpenter; Edward F Attiyeh; Sharon J Diskin; Sunkyu Kim; Sudha Parasuraman; Giordano Caponigro; Robert W Schnepp; Andrew C Wood; Bruce Pawel; Kristina A Cole; John M Maris
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.